Achondroplasia (ACH) has long been an extremely intractable disease in children characterized by both rhizomelic shortened limbs and considerable shot stature. In the July issue, a world-renowned endocrinologist, Dr. Keiichi Ozono and colleague provide an inspirational and cutting-edge review on the update of molecular mechanisms and brand-new therapeutic modalities for ACH. Our editorial team has a firm belief that such a “making the impossible possible” story in the translational research of endocrinology is a must-read for all readers in Endocrine Journal.
![EJ24-0109](https://endocrine-j.jp/wp-content/uploads/EJ24-0109FA.jpg")
Recommendation from the Editor in Chief
Achondroplasia (ACH) has long been an extremely intractable disease in children characterized by both rhizomelic shortened limbs and considerable shot stature. In the July issue, a world-renowned endocrinologist, Dr. Keiichi Ozono and colleague provide an inspirational and cutting-edge review on the update of molecular mechanisms and brand-new therapeutic modalities for ACH. Our editorial team has a firm belief that such a “making the impossible possible” story in the translational research of endocrinology is a must-read for all readers in Endocrine Journal.